Evidence map›Paper›PMID 33235904›Full record

ArticleMolecular & cellular oncology2020

Unconventional role of RAC1 in MET-driven anchorage-independent tumor growth.

Alexia Hervieu, Stéphanie Kermorgant

Open access · hybridAbstract read
In one paragraph

Article in Molecular & cellular oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Alexia HervieuSpatial Signalling Team, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK.ORCID https://orcid.org/0000-0002-8061-6678
Stéphanie KermorgantSpatial Signalling Team, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK.ORCID https://orcid.org/0000-0001-5921-479X
Institute of Cancer Research · GBQueen Mary University of London · GB

Funding

Medical Research Council G0501003Medical Research Council MR/R009732/1
6 · The paper itself

Abstract

We reported that RAC1 is a master regulator of cell migration and anchorage-independent growth, downstream of the oncogenic Receptor Tyrosine Kinase (RTK) MET. RAC1 growth-promoting role is guanosine triphosphatase (GTPase)- and phosphatidylinositol 3-kinase (PI3K)-independent but promotes mammalian target of rapamycin (mTOR) signaling through triggering its plasma membrane localization.

Indexed as

METmTORPI3KRAC1

Identifiers

PMID33235904
PMCPMC7671004
OpenAlexW3063748325

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.